Capital Analysts LLC’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $742K | Buy |
12,238
+773
| +7% | +$45.1K | 0.02% | 381 |
|
|
2025
Q4 | $619K | Sell |
11,465
-1,363
| -11% | -$65.6K | 0.02% | 395 |
|
|
2025
Q3 | $579K | Sell |
12,828
-141
| -1% | -$6.58K | 0.02% | 396 |
|
|
2025
Q2 | $601K | Sell |
12,969
-25
| -0.2% | -$1.23K | 0.02% | 362 |
|
|
2025
Q1 | $793K | Sell |
12,994
-431
| -3% | -$25.1K | 0.03% | 296 |
|
|
2024
Q4 | $759K | Sell |
13,425
-458
| -3% | -$25.6K | 0.03% | 277 |
|
|
2024
Q3 | $718K | Buy |
13,883
+4,352
| +46% | +$204K | 0.03% | 280 |
|
|
2024
Q2 | $396K | Buy |
9,531
+121
| +1% | +$5.41K | 0.02% | 361 |
|
|
2024
Q1 | $510K | Buy |
9,410
+1,270
| +16% | +$64.7K | 0.02% | 311 |
|
|
2023
Q4 | $418K | Sell |
8,140
-2,201
| -21% | -$116K | 0.02% | 335 |
|
|
2023
Q3 | $600K | Sell |
10,341
-534
| -5% | -$32.7K | 0.03% | 276 |
|
|
2023
Q2 | $696K | Sell |
10,875
-466
| -4% | -$31.2K | 0.04% | 259 |
|
|
2023
Q1 | $786K | Sell |
11,341
-342
| -3% | -$24.1K | 0.05% | 244 |
|
|
2022
Q4 | $840K | Buy |
11,683
+333
| +3% | +$25.1K | 0.05% | 232 |
|
|
2022
Q3 | $807K | Buy |
11,350
+404
| +4% | +$29.3K | 0.06% | 228 |
|
|
2022
Q2 | $843K | Buy |
10,946
+104
| +1% | +$7.92K | 0.06% | 222 |
|
|
2022
Q1 | $791K | Buy |
10,842
+1,849
| +21% | +$124K | 0.05% | 233 |
|
|
2021
Q4 | $561K | Buy |
8,993
+893
| +11% | +$52.4K | 0.03% | 258 |
|
|
2021
Q3 | $479K | Buy |
8,100
+1,137
| +16% | +$74.9K | 0.03% | 263 |
|
|
2021
Q2 | $465K | Sell |
6,963
-157
| -2% | -$10.2K | 0.03% | 264 |
|
|
2021
Q1 | $449K | Buy |
7,120
+3,120
| +78% | +$194K | 0.03% | 262 |
|
|
2020
Q4 | $248K | Sell |
4,000
-461
| -10% | -$28.3K | 0.02% | 231 |
|
|
2020
Q3 | $269K | Buy |
4,461
+8
| +0.2% | +$481 | 0.03% | 233 |
|
|
2020
Q2 | $262K | Buy |
4,453
+483
| +12% | +$28.9K | 0.03% | 210 |
|
|
2020
Q1 | $221K | Sell |
3,970
-336
| -8% | -$20.5K | 0.03% | 202 |
|
|
2019
Q4 | $276K | Buy |
4,306
+91
| +2% | +$5.21K | 0.03% | 214 |
|
|
2019
Q3 | $213K | Sell |
4,215
-49
| -1% | -$2.3K | 0.02% | 217 |
|
|
2019
Q2 | $193K | Buy |
4,264
+692
| +19% | +$32.2K | 0.02% | 223 |
|
|
2019
Q1 | $170K | Buy |
3,572
+453
| +15% | +$22.6K | 0.02% | 223 |
|
|
2018
Q4 | $162K | Hold |
3,119
| – | – | 0.02% | 212 |
|
|
2018
Q3 | $194K | Hold |
3,119
| – | – | 0.02% | 194 |
|
|
2018
Q2 | $173K | Buy |
3,119
+450
| +17% | +$24.3K | 0.02% | 204 |
|
|
2018
Q1 | $169K | Buy |
2,669
+483
| +22% | +$31.1K | 0.02% | 198 |
|
|
2017
Q4 | $134K | Sell |
2,186
-367
| -14% | -$23K | 0.02% | 209 |
|
|
2017
Q3 | $163K | Hold |
2,553
| – | – | 0.02% | 199 |
|
|
2017
Q2 | $142K | Sell |
2,553
-3,820
| -60% | -$208K | 0.02% | 211 |
|
|
2017
Q1 | $347K | Buy |
6,373
+160
| +3% | +$8.78K | 0.05% | 155 |
|
|
2016
Q4 | $363K | Sell |
6,213
-31,462
| -84% | -$1.72M | 0.06% | 160 |
|
|
2016
Q3 | $2.03M | Buy |
37,675
+6,222
| +20% | +$400K | 0.38% | 69 |
|
|
2016
Q2 | $2.31M | Buy |
31,453
+1,956
| +7% | +$138K | 0.47% | 60 |
|
|
2016
Q1 | $1.88M | Buy |
29,497
+29,297
| +14,649% | +$1.85M | 0.38% | 74 |
|
|
2015
Q4 | $13.8K | Buy |
+200
| New | +$13.2K | ﹤0.01% | 343 |
|
|
2013
Q3 | – | Sell |
-20,245
| Closed | -$905K | – | 310 |
|
|
2013
Q2 | $905K | Buy |
+20,245
| New | +$879K | 0.29% | 89 |
|
Other funds holding BMY
VCM
VPM
Capital Analysts LLC's BMY Position: Q1 2026 in Review
Capital Analysts LLC increased its Bristol-Myers Squibb (BMY) stake by 6.7% in Q1 2026, buying an estimated $45.1K and bringing the position to 12,238 shares worth $742K. The position accounts for 0.02% of the portfolio, ranked #381.
Capital Analysts LLC first reported a position in BMY in Q2 2013 and has held it in 43 quarters since. The position peaked at $2.31M in Q2 2016. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Capital Analysts LLC held 12,238 shares of Bristol-Myers Squibb worth $742K as of Q1 2026.
- Capital Analysts LLC bought 773 Bristol-Myers Squibb shares in Q1 2026, an estimated $45.1K.
- Bristol-Myers Squibb made up 0.02% of Capital Analysts LLC's portfolio in Q1 2026, its #381 holding.
- Capital Analysts LLC first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 43 quarters since.
- Capital Analysts LLC's Bristol-Myers Squibb position peaked at $2.31M in Q2 2016.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.